University of Pennsylvania drives new discoveries in cancer immunotherapy research on an international scale, and pioneered the first FDA-approved CAR-T cell therapy. Penn’s award-winning doctors and scientists focus on training immune cells to recognize and hunt cancer cells. PICI at Penn extends this work and supports laboratory studies and clinical trials, recruitment of talented new faculty and opportunities for early-career investigators who will train at Penn. Carl June, MD | Director E. John Wherry, PhD | Co-Director All Investigators Related Our Impact, Press Release, Research Update For Advanced Pancreatic Cancer, Combining Immunotherapies with Chemotherapy Shows Early Promise in Reducing Tumor Size Clinical Trial The PRINCE Trial Research Update A Bubble of Hope for Cancer: the Exosome in Immunotherapy Press Release Parker Institute researchers publish first major scientific paper in Nature Announcement, Press Release Parker Institute Commits Additional $125M for Audacious Mission to Cure Cancer Announcement, Press Release The Parker Institute for Cancer Immunotherapy Awards More Than $1 Million to Four Early Career Investigators Announcement Behind the Breakthrough: An Interview with Carl June, the Father of CAR T-Cell Therapy Announcement PICI Network Investigators to Showcase Immunotherapy Advances at ASCO 2024 Announcement Unlocking Complex Cell-based Gene Therapies: A Joint Workshop Hosted by PICI and FOCR
Our Impact, Press Release, Research Update For Advanced Pancreatic Cancer, Combining Immunotherapies with Chemotherapy Shows Early Promise in Reducing Tumor Size
Announcement, Press Release Parker Institute Commits Additional $125M for Audacious Mission to Cure Cancer
Announcement, Press Release The Parker Institute for Cancer Immunotherapy Awards More Than $1 Million to Four Early Career Investigators